• Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Analysts

    Source: Buzz FX / 03 Mar 2025 04:26:14   America/Chicago


    Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Analysts Written by MarketBeat March 3, 2025 Share Link copied to clipboard. Keros Therapeutics, Inc. ( NASDAQ:KROS - Get Free Report ) has earned a con
    Read more...
Share on,